Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders Dec 23, 2019
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency Dec 09, 2019
Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights Nov 12, 2019